Market Cap (In USD)
21.13 Million
Revenue (In USD)
-
Net Income (In USD)
-25.96 Million
Avg. Volume
6.38 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.09-11.18
- PE
- -
- EPS
- -
- Beta Value
- 3.109
- ISIN
- US3736786068
- CUSIP
- 373678507
- CIK
- 832489
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David Alan Dodd
- Employee Count
- -
- Website
- https://www.geovax.com
- Ipo Date
- 2020-09-25
- Details
- GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
More Stocks
-
LW
-
CCDBFCCL Industries Inc.
CCDBF
-
AXISBANKAxis Bank Limited
AXISBANK
-
MSTI
-
AEC
-
TIGO-SDBMillicom International Cellular S.A.
TIGO-SDB
-
SEG
-
CLAS-BClas Ohlson AB (publ)
CLAS-B